You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Lymphoma Drug Receives Accelerated Approval

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000407288.47749.4c
Drug Watch
Abstract

* Brentuximab (Adcetris), an antibody–drug conjugate, has been given accelerated approval to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.

* The drug label warns of the following serious adverse effects: peripheral neuropathy, neutropenia, infusion reactions, tumor lysis syndrome, Stevens–Johnson syndrome, progressive multifocal leukoencephalopathy, and teratogenesis.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2011 Lippincott Williams & Wilkins, Inc.